Theravance Biopharma (TBPH) Gross Margin (2013 - 2018)
Theravance Biopharma (TBPH) reported Gross Margin of 90.07% for Q1 2018, up 837.0% year-over-year from 9.61% in Q1 2017, and up 190.69% quarter-over-quarter from 30.99% in Q4 2017.
Theravance Biopharma (TBPH) Gross Margin (2013 - 2018) Analysis & Trends
Theravance Biopharma (TBPH) has 6 years of Gross Margin data on file, last reported at 90.07% in Q1 2018.
- Gross Margin for Q1 2018 came in at 90.07%, up 837.0% year-over-year; the trailing twelve-month figure through Mar 2018 was 69.49% (down 2247.0% YoY), and the FY2017 annual result was 60.81%, down 1990.0% from the prior year.
- Gross Margin climbed to 90.07% in Q1 2018 per TBPH's latest filing, from 30.99% in the prior quarter.
- Over five years, Gross Margin peaked at 98.26% in Q3 2016 and troughed at 124.84% in Q4 2014.
- A 5-year average of 67.45% and a median of 88.34% in 2016 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2014 and 2015: Gross Margin plunged 22484 bps in 2014, then jumped 14262 bps in 2015.
- A 5-year view of Gross Margin shows it stood at 124.84% in 2014, then soared by 114 bps to 17.78% in 2015, then jumped by 349 bps to 79.87% in 2016, then plunged by 61 bps to 30.99% in 2017, then soared by 191 bps to 90.07% in 2018.
- Business Quant data shows TBPH's Gross Margin at 90.07% in Q1 2018, 30.99% in Q4 2017, and 76.96% in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 90.07% |
| Dec 31, 2017 | 30.99% |
| Sep 30, 2017 | 76.96% |
| Jun 30, 2017 | 61.13% |
| Mar 31, 2017 | 81.70% |
| Dec 31, 2016 | 79.87% |
| Sep 30, 2016 | 98.26% |
| Jun 30, 2016 | 88.34% |
| Mar 31, 2016 | 95.77% |
| Dec 31, 2015 | 17.78% |
| Sep 30, 2015 | 94.57% |
| Jun 30, 2015 | 92.92% |
| Mar 31, 2015 | 98.18% |
| Dec 31, 2014 | -124.84% |
| Sep 30, 2014 | 94.18% |
| Jun 30, 2014 | 90.62% |
| Mar 31, 2014 | 80.11% |
| Dec 31, 2013 | 100.00% |
| Sep 30, 2013 | 100.00% |
| Jun 30, 2013 | 100.00% |